Al Hammadi‘s net profit drops 9% in 9M 2019

28/10/2019 Argaam Exclusive

View other reports

Share Price

48.60
0.35 0.73 %

Al Hammadi Holding (ALHAMMADI)

Al Hammadi Company for Development and Investment posted a net profit of SAR 65.35 million for the first nine months of 2019, a 9.38 percent decline as compared to SAR 72.12 million in the same period in 2018.

 



Financials (M)

Item 9m 2018 9m 2019 Change‬
Revenues 665.56 703.51 5.7 %
Gross Income 185.04 198.90 7.5 %
Operating Income 97.74 89.99 (7.9 %)
Net Income 72.12 65.35 (9.4 %)
Average Shares 160.00 160.00 -
EPS (Riyals) 0.45 0.41 (9.4 %)

The company attributed the decrease in earnings to the increase in operating expenses, administrative salaries and depreciation expenses related to Nuzha Hospital, which opened in Feb. 2018 in addition to the increase in the subsidiary company expenses.

 

In Q3 2019, the company posted a net profit after zakat and tax of SAR 21.17 million, a 0.65 percent fall as compared to SAR 21.31 million in the same period last year on decrease in pharmaceuticals sales of the subsidiary firm.

 

On a quarterly basis, the company posted a 5.7 percent rise in net profit.



Current Quarter Comparison (M)

Compared With The
Item Q3 2018 Q3 2019 Change‬
Revenues 250.40 220.00 (12.1 %)
Gross Income 64.92 62.22 (4.2 %)
Operating Income 31.19 31.85 2.1 %
Net Income 21.31 21.17 (0.6 %)
Average Shares 160.00 160.00 -
EPS (Riyals) 0.13 0.13 (0.6 %)


Financial results (Million)

Period Revenues Change Gross Income Change Net Income Change EPS(Riyal)
Q1 2010 - - - - - - -
Q2 2010 - - - - - - -
Q3 2010 - - - - - - -
Q4 2010 - - - - - - -
Q1 2011 - - - - - - -
Q2 2011 - - - - - - -
Q3 2011 - - - - - - -
Q4 2011 - - - - - - -
Q1 2012 - - - - - - -
Q2 2012 - - - - - - -
Q3 2012 - - - - - - -
Q4 2012 - - - - - - -
Q1 2013 104.84 - 47.34 - 29.83 - 0.19
Q2 2013 108.85 - 45.84 - 30.06 - 0.19
Q3 2013 96.26 - 36.81 - 18.32 - 0.11
Q4 2013 124.13 - 55.17 - 33.29 - 0.21
Q1 2014 122.04 16.4 % 54.71 15.6 % 34.23 14.7 % 0.21
Q2 2014 121.66 11.8 % 53.68 17.1 % 35.60 18.4 % 0.22
Q3 2014 108.83 13.1 % 44.74 21.5 % 25.42 38.7 % 0.16
Q4 2014 129.43 4.3 % 55.99 1.5 % 33.71 1.2 % 0.21
Q1 2015 129.48 6.1 % 50.64 (7.4 %) 41.01 19.8 % 0.26
Q2 2015 137.36 12.9 % 63.56 18.4 % 36.89 3.6 % 0.23
Q3 2015 136.80 25.7 % 57.97 29.6 % 27.69 8.9 % 0.17
Q4 2015 157.70 21.8 % 68.06 21.6 % 35.75 6.0 % 0.22
Q1 2016 144.16 11.3 % 54.75 8.1 % 21.14 (48.5 %) 0.13
Q2 2016 138.08 0.5 % 57.56 (9.5 %) 20.63 (44.1 %) 0.13
Q3 2016 141.35 3.3 % 56.48 (2.6 %) 20.73 (25.1 %) 0.13
Q4 2016 182.65 15.8 % 73.35 7.8 % 10.48 (70.7 %) 0.07
Q1 2017 180.23 25.0 % 62.02 13.3 % 27.97 32.3 % 0.17
Q2 2017 176.71 28.0 % 58.16 1.0 % 25.66 24.4 % 0.16
Q3 2017 163.01 15.3 % 53.91 (4.5 %) 23.59 13.8 % 0.15
Q4 2017 188.69 3.3 % 65.08 (11.3 %) 30.76 193.4 % 0.19
Q1 2018 200.67 11.3 % 66.84 7.8 % 30.88 10.4 % 0.19
Q2 2018 214.49 21.4 % 53.28 (8.4 %) 19.93 (22.3 %) 0.12
Q3 2018 250.40 53.6 % 64.92 20.4 % 21.31 (9.7 %) 0.13
Q4 2018 228.04 20.9 % 65.32 0.4 % 17.70 (42.5 %) 0.11
Q1 2019 229.68 14.5 % 65.60 (1.9 %) 24.17 (21.7 %) 0.15
Q2 2019 253.83 18.3 % 71.08 33.4 % 20.01 0.4 % 0.13
Q3 2019 220.00 (12.1 %) 62.22 (4.2 %) 21.17 (0.6 %) 0.13

Profitability

Period Gross Margin OIBDA Margin Net Margin Before Unusual Items
Q1 2010 - - -
Q2 2010 - - -
Q3 2010 - - -
Q4 2010 - - -
Q1 2011 - - -
Q2 2011 - - -
Q3 2011 - - -
Q4 2011 - - -
Q1 2012 - - -
Q2 2012 - - -
Q3 2012 - - -
Q4 2012 - - -
Q1 2013 - - -
Q2 2013 - - -
Q3 2013 - - -
Q4 2013 42.66 % 27.60 % 24.31 %
Q1 2014 42.66 % 27.85 % 24.35 %
Q2 2014 43.18 % 29.90 % 26.17 %
Q3 2014 43.70 % 30.34 % 26.97 %
Q4 2014 43.39 % 30.09 % 26.75 %
Q1 2015 41.90 % 29.13 % 25.73 %
Q2 2015 42.55 % 28.68 % 25.19 %
Q3 2015 42.80 % 29.71 % 24.29 %
Q4 2015 42.80 % 31.06 % 23.43 %
Q1 2016 42.42 % 30.79 % 21.09 %
Q2 2016 41.32 % 30.64 % 18.24 %
Q3 2016 40.74 % 29.96 % 16.90 %
Q4 2016 39.94 % 25.11 % 12.04 %
Q1 2017 38.83 % 24.74 % 12.43 %
Q2 2017 36.71 % 24.09 % 12.46 %
Q3 2017 35.22 % 23.41 % 12.48 %
Q4 2017 33.75 % 25.39 % 15.24 %
Q1 2018 33.46 % 26.03 % 15.21 %
Q2 2018 31.18 % 25.45 % 13.71 %
Q3 2018 29.28 % 24.60 % 12.04 %
Q4 2018 28.02 % 24.14 % 10.05 %
Q1 2019 27.00 % 22.96 % 9.01 %
Q2 2019 27.75 % 22.56 % 8.65 %
Q3 2019 28.36 % 23.59 % 8.92 %


Per Share Data (Riyal)

Compared With The
Period Shares Outstanding (M) EPS (Riyal) Adjusted EPS (Riyal) Book Value (BV)
Q1 2010 - - - -
Q2 2010 - - - -
Q3 2010 - - - -
Q4 2010 - - - -
Q1 2011 - - - -
Q2 2011 - - - -
Q3 2011 - - - -
Q4 2011 - - - -
Q1 2012 - - - -
Q2 2012 - - - -
Q3 2012 - - - -
Q4 2012 - - - -
Q1 2013 160.00 - - 3.74
Q2 2013 160.00 - - 3.67
Q3 2013 160.00 - - 3.78
Q4 2013 160.00 0.70 0.66 3.66
Q1 2014 160.00 0.72 0.69 3.87
Q2 2014 160.00 0.76 0.76 7.88
Q3 2014 160.00 0.80 0.80 8.04
Q4 2014 160.00 0.81 0.81 8.25
Q1 2015 160.00 0.85 0.79 8.51
Q2 2015 160.00 0.86 0.80 8.27
Q3 2015 160.00 0.87 0.81 8.44
Q4 2015 160.00 0.88 0.82 8.66
Q1 2016 160.00 0.76 0.76 8.80
Q2 2016 160.00 0.66 0.66 8.37
Q3 2016 160.00 0.61 0.61 8.50
Q4 2016 160.00 0.46 0.46 8.56
Q1 2017 160.00 0.50 0.50 8.75
Q2 2017 160.00 0.53 0.53 8.89
Q3 2017 160.00 0.55 0.55 9.04
Q4 2017 160.00 0.67 0.67 8.67
Q1 2018 160.00 0.69 0.69 8.85
Q2 2018 160.00 0.66 0.66 8.98
Q3 2018 160.00 0.64 0.64 9.11
Q4 2018 160.00 0.56 0.56 9.24
Q1 2019 160.00 0.52 0.52 9.40
Q2 2019 160.00 0.52 0.52 9.51
Q3 2019 160.00 0.52 0.52 9.63

Multiple Ratios (End of Period Price)

Compared With The
Period P/E Adjusted P/E Price/book
Q1 2010 - - -
Q2 2010 - - -
Q3 2010 - - -
Q4 2010 - - -
Q1 2011 - - -
Q2 2011 - - -
Q3 2011 - - -
Q4 2011 - - -
Q1 2012 - - -
Q2 2012 - - -
Q3 2012 - - -
Q4 2012 - - -
Q1 2013 - - -
Q2 2013 - - -
Q3 2013 - - -
Q4 2013 - - -
Q1 2014 - - -
Q2 2014 - - -
Q3 2014 51.42 51.42 5.14
Q4 2014 48.92 48.92 4.78
Q1 2015 51.53 55.54 5.14
Q2 2015 54.13 58.30 5.61
Q3 2015 44.33 47.69 4.57
Q4 2015 41.63 44.73 4.24
Q1 2016 36.41 36.41 3.14
Q2 2016 45.86 45.86 3.60
Q3 2016 36.32 36.32 2.62
Q4 2016 68.31 68.31 3.64
Q1 2017 61.37 61.37 3.50
Q2 2017 58.51 58.51 3.49
Q3 2017 47.94 47.94 2.91
Q4 2017 41.25 41.25 3.21
Q1 2018 39.28 39.28 3.07
Q2 2018 37.68 37.68 2.76
Q3 2018 32.21 32.21 2.27
Q4 2018 33.55 33.55 2.04
Q1 2019 35.91 35.91 1.98
Q2 2019 30.97 30.97 1.69
Q3 2019 32.09 32.09 1.73

Business Segments (Million)

Compared With The
Period healthy services and other Pharmaceutical sales revenue - Pharmacies
Q1 2017 150.74 29.49
Q2 2017 147.45 29.26
Q3 2017 136.70 26.31
Q4 2017 155.95 32.73
Q1 2018 140.85 59.82
Q2 2018 143.64 71.39
Q3 2018 140.83 109.03
Q4 2018 154.81 73.23
Q1 2019 146.91 82.77
Q2 2019 151.05 102.78
Q3 2019 149.00 71.00

Analysts Estimates (Million)

Item Q3 2019 (e) Q3 2019 (a) Change‬
Average 23.53 21.17 (10.0 %)

Estimates vs Actual (Million)

Item Q3 2019 (e) Q3 2019 (a) Change
OSOOL AND BAKHEET 21.20 21.17 (0.2) %
AlJazira Capital 21.90 21.17 (3.3) %
SNB Capital 23.00 21.17 (8.0) %
Al Rajhi Capital 28.00 21.17 (24.4) %

Current
Market Cap (M Riyal) 7,776.00
Enterprise Value (EV) (M) 7,774.11
Shares Outstanding ((M)) 160.00
EPS ( Riyal) (TTM) 1.79
Book Value (BV) ( Riyal) 11.58
Par Value ( Riyal) 10.00
Adjusted P/E (Last12) 27.82
P/E (TTM) 27.19
Price/book 4.20
Return on Average Assets (%) (TTM) 11.1
Return on Average Equity (%) (TTM) 15.9

Comments {{getCommentCount()}}

Be the first to comment

{{Comments.indexOf(comment)+1}}
{{comment.FollowersCount}}
{{comment.CommenterComments}}
loader Train
Sorry: the validity period has ended to comment on this news
Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.